J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
Johnson & Johnson said Monday it will snap up Ollin Biosciences in a deal worth up to $3.3 billion, just a little over a year after the ophthalmology biotech broke cover ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.